Is Zomedica Pharmaceuticals Corp’s Fuel For Real? The Stock Just Upped Again

 Is Zomedica Pharmaceuticals Corp's Fuel For Real? The Stock Just Upped Again

The stock of Zomedica Pharmaceuticals Corp (CVE:ZOM) is a huge mover today! About 31,624 shares traded hands or 789.06% up from the average. Zomedica Pharmaceuticals Corp (CVE:ZOM) has risen 6.00% since October 10, 2016 and is uptrending. It has outperformed by 1.22% the S&P500.
The move comes after 9 months positive chart setup for the $145.74 million company. It was reported on Nov, 9 by Barchart.com. We have $5.09 PT which if reached, will make CVE:ZOM worth $278.36M more.

More notable recent Zomedica Pharmaceuticals Corp (CVE:ZOM) news were published by: Marketwatch.com which released: “Zomedica Pharmaceuticals Corp. Opens the Market” on May 03, 2016, also Globenewswire.com with their article: “Zomedica Pharmaceuticals Corp. Announces First Quarter 2016 Financial Results …” published on May 26, 2016, Globenewswire.com published: “Zomedica Announces Completion of Qualifying Transaction” on April 27, 2016. More interesting news about Zomedica Pharmaceuticals Corp (CVE:ZOM) were released by: Crainsdetroit.com and their article: “Zomedica aims to specialize in pet pharma” published on August 28, 2016 as well as Globenewswire.com‘s news article titled: “ZoMedica To Complete Listing Transaction on TSX Venture Exchange” with publication date: April 13, 2016.

Zomedica Pharmaceuticals Corp., formerly Wise Oakwood Ventures Inc., is a Canada veterinary pharmaceutical company. The company has a market cap of $145.74 million. The Firm focuses on health and wellness solutions for companion animals, such as canine, feline and equine. It currently has negative earnings. The Firm is engaged in building a portfolio of products comprised of the discovery, development and commercialization of drugs alongside drug delivery systems, devices and diagnostics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment